July 16, 2025 07:40 AM EDTUpdated 10:34 AM
R&D

Up­dat­ed: J&J's Ste­lara faces con­tin­ued biosim­i­lar com­pe­ti­tion, with Q2 rev­enue falling 43%

Max Gelman

Senior Editor

John­son & John­son said rev­enue for its megablock­buster Ste­lara con­tin­ued to de­cline in the face of emerg­ing biosim­i­lar com­pe­ti­tion.

The

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PureTech CEO leaves just one week af­ter long­time chair steps down

Prime Med­i­cine CSO de­parts, re­veals new fund­ing; FDA lifts par­tial hold on Kezar drug

As­traZeneca says amy­loi­do­sis drug fails Phase 3 tri­als, but claims po­ten­tial in undis­closed sub­group

Prasad again over­rode FDA vac­cine re­view­ers, this time on Mod­er­na’s Covid shot for young kids

De­bio­pharm li­cens­es Re­pare’s first-in-class can­cer drug for $10M up­front

Jeanne Mar­raz­zo, NI­AID di­rec­tor placed on leave, on 'biggest threat­s' to HIV med­i­cine

A service from the Financial Times